Optimization of LY545694 Tosylate Controlled Release Tablets Through Pharmacoscintigraphy

• Published in: Pharmaceutical research Vol. 29; no. 10; pp. 2912 - 2925
• Main Authors: Lobo, Evelyn D., Argentine, Mark D., Sperry, David C., Connor, Alyson, McDermott, John, Stevens, Lloyd, Almaya, Ahmad
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.10.2012; Springer; Springer Nature B.V
• Subjects: Absorption; Adult; Area Under Curve; Benzenesulfonates - administration & dosage; Benzenesulfonates - chemistry; Benzenesulfonates - pharmacokinetics; Bioavailability; Biochemistry; Biological and medical sciences; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Chemistry, Pharmaceutical - methods; Delayed-Action Preparations; Drug delivery systems; Drug dosages; Excitatory Amino Acid Antagonists - administration & dosage; Excitatory Amino Acid Antagonists - chemistry; Excitatory Amino Acid Antagonists - pharmacokinetics; Gastrointestinal Tract - metabolism; General pharmacology; Humans; Kinetics; Male; Medical Law; Medical sciences; Pharmaceutical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacy; Prodrugs - administration & dosage; Prodrugs - chemistry; Prodrugs - pharmacokinetics; Receptors, Glutamate - metabolism; Research Paper; Tablets - chemistry; Young Adult; prodrug; pharmacokinetics; flexible design space; absorption; controlled-release; Space; Pharmaceutical technology; Controlled release form; Control release polymer; Prodrug; Optimization; Design; Absorption; Dosage form; Tablet; Pharmacokinetics
• DOI: 10.1007/s11095-012-0798-1
• ISSN: 0724-8741; 1573-904X

ABSTRACT Purpose To optimize a controlled release (CR) matrix formulation with two goals: (1) effectively deliver a prodrug to a preferred absorption region of the upper GI tract, and (2) afford a PK profile similar to a “reference” CR formulation. Methods A pharmacoscintigraphic clinical study was conducted using a flexible formulation design space. A six-arm, three-prototype study was employed to cover the formulation design space and assess performance against the reference formulation. Pharmacokinetic and scintigraphic data from the first three dosing arms were used to select prototypes to be dosed in subsequent arms. Results Of three prototypes tested, the third prototype had an optimal release rate. The in vivo erosion rate was observed via scintigraphy to reach 90% in 3 h. The AUC ratio relative to the reference for the prodrug was 1.25, while the C max ratio was 1.07. The ratios for the active moiety were 1.31 (AUC) and 1.01 (C max ). Conclusions A single pharmacoscintigraphic study efficiently investigated a wide formulation design space and precisely optimized the release rate with few formulation iterations. The selected formulation provided the desired exposure at a 30% lower dose. The approach is beneficial when drug absorption is limited to a region of the GI tract.